JP6516743B2 - オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 - Google Patents

オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 Download PDF

Info

Publication number
JP6516743B2
JP6516743B2 JP2016533614A JP2016533614A JP6516743B2 JP 6516743 B2 JP6516743 B2 JP 6516743B2 JP 2016533614 A JP2016533614 A JP 2016533614A JP 2016533614 A JP2016533614 A JP 2016533614A JP 6516743 B2 JP6516743 B2 JP 6516743B2
Authority
JP
Japan
Prior art keywords
fluorophenyl
sulfonyl
pyrazolo
octahydro
isoquinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016533614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537394A (ja
JP2016537394A5 (enExample
Inventor
ヘイゼル ハント，
ヘイゼル ハント，
イアン ウォルターズ，
イアン ウォルターズ，
ブノワ グールデット，
ブノワ グールデット，
Original Assignee
コーセプト セラピューティクス， インコーポレイテッド
コーセプト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーセプト セラピューティクス， インコーポレイテッド, コーセプト セラピューティクス， インコーポレイテッド filed Critical コーセプト セラピューティクス， インコーポレイテッド
Publication of JP2016537394A publication Critical patent/JP2016537394A/ja
Publication of JP2016537394A5 publication Critical patent/JP2016537394A5/ja
Application granted granted Critical
Publication of JP6516743B2 publication Critical patent/JP6516743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016533614A 2013-11-25 2014-11-21 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 Active JP6516743B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361908333P 2013-11-25 2013-11-25
US61/908,333 2013-11-25
US201461985035P 2014-04-28 2014-04-28
US61/985,035 2014-04-28
PCT/US2014/066759 WO2015077530A1 (en) 2013-11-25 2014-11-21 Octahydro fused azadecalin glucocorticoid receptor modulators

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017206081A Division JP2018012734A (ja) 2013-11-25 2017-10-25 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2019063279A Division JP2019094355A (ja) 2013-11-25 2019-03-28 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子

Publications (3)

Publication Number Publication Date
JP2016537394A JP2016537394A (ja) 2016-12-01
JP2016537394A5 JP2016537394A5 (enExample) 2017-12-07
JP6516743B2 true JP6516743B2 (ja) 2019-05-22

Family

ID=53180165

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016533614A Active JP6516743B2 (ja) 2013-11-25 2014-11-21 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2017206081A Pending JP2018012734A (ja) 2013-11-25 2017-10-25 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2019063279A Withdrawn JP2019094355A (ja) 2013-11-25 2019-03-28 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2021021630A Withdrawn JP2021073315A (ja) 2013-11-25 2021-02-15 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2022189246A Withdrawn JP2023011052A (ja) 2013-11-25 2022-11-28 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2024148322A Pending JP2024170470A (ja) 2013-11-25 2024-08-30 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017206081A Pending JP2018012734A (ja) 2013-11-25 2017-10-25 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2019063279A Withdrawn JP2019094355A (ja) 2013-11-25 2019-03-28 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2021021630A Withdrawn JP2021073315A (ja) 2013-11-25 2021-02-15 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2022189246A Withdrawn JP2023011052A (ja) 2013-11-25 2022-11-28 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
JP2024148322A Pending JP2024170470A (ja) 2013-11-25 2024-08-30 オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子

Country Status (20)

Country Link
US (8) US10047082B2 (enExample)
EP (4) EP4219494A1 (enExample)
JP (6) JP6516743B2 (enExample)
KR (1) KR102352737B1 (enExample)
CN (2) CN109761976B (enExample)
AU (1) AU2014352915B2 (enExample)
BR (1) BR112016011826B1 (enExample)
CA (1) CA2931302C (enExample)
DK (2) DK3848027T3 (enExample)
ES (3) ES2869172T3 (enExample)
FI (1) FI3848027T3 (enExample)
IL (1) IL245848B (enExample)
MX (1) MX368167B (enExample)
MY (1) MY180141A (enExample)
PH (1) PH12016500968B1 (enExample)
PL (3) PL3074011T3 (enExample)
PT (2) PT3848027T (enExample)
RU (1) RU2674983C1 (enExample)
WO (1) WO2015077530A1 (enExample)
ZA (1) ZA201604026B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514849B2 (en) 2018-12-19 2026-01-06 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3074011T3 (pl) 2013-11-25 2020-01-31 Corcept Therapeutics Incorporated Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego
MX383353B (es) 2015-03-30 2025-03-13 Corcept Therapeutics Inc Uso de antagonistas de receptores de glucocorticoides en combinacion con glucocorticoides para tratar la insuficiencia adrenal.
AU2017228329B2 (en) 2016-03-01 2021-03-11 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
CN106478464B (zh) * 2016-08-30 2018-06-05 黄河三角洲京博化工研究院有限公司 一种2-氟-6-三氟甲基苯磺酰氯的制备方法
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
WO2018165460A1 (en) 2017-03-09 2018-09-13 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
MX2019011543A (es) 2017-03-31 2019-12-16 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
WO2018209142A2 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
CN117771239A (zh) * 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
EP3784658B1 (en) * 2018-04-23 2025-08-20 Corcept Therapeutics Incorporated Methods of preparing regioselective n-alkyl triazoles
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11058670B2 (en) * 2019-02-22 2021-07-13 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
MX2022004487A (es) 2019-10-16 2022-05-06 Corcept Therapeutics Inc Metodo para normalizar el indice de neutrofilos a linfocitos en pacientes con cancer con un antagonista del receptor de glucocorticoide selectivo.
WO2021119432A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
WO2021127376A1 (en) 2019-12-21 2021-06-24 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
WO2021154750A1 (en) 2020-01-29 2021-08-05 Corcept Therapeutics Incorporated TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
CN115397418A (zh) * 2020-02-10 2022-11-25 科赛普特治疗学股份有限公司 使用选择性糖皮质激素受体调节剂刺激抗肿瘤反应的方法
MX2022016445A (es) 2020-06-22 2023-02-01 Corcept Therapeutics Inc Antagonistas del receptor de glucocorticoides de indazol cuaternario.
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2022166810A1 (zh) * 2021-02-03 2022-08-11 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
EP4452968A4 (en) 2021-12-21 2025-12-10 Corcept Therapeutics Inc INDAZOLE GLUCOCORTICOID RECEPTOR BICYCLIC ANTAGONISTS
CA3243549A1 (en) 2021-12-21 2023-06-29 Corcept Therapeutics Incorporated INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS
EP4598513A1 (en) 2022-10-06 2025-08-13 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
IL320512A (en) 2022-10-28 2025-06-01 Corcept Therapeutics Inc Amyotrophic lateral sclerosis treatments using desocorilant
AU2024223250A1 (en) * 2023-02-17 2025-08-14 Corcept Therapeutics Incorporated Methods and compositions for treating huntington's disease and its symptoms
WO2024243185A1 (en) * 2023-05-22 2024-11-28 Corcept Therapeutics Incorporated Methods for treating adrenal gland tumors
TW202539687A (zh) * 2024-01-15 2025-10-16 香港商英矽智能科技知識產權有限公司 作為糖皮質激素受體調節劑的新化合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS322220B1 (enExample) 1954-11-30 1957-04-11
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
IL72729A (en) 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
CN1043641C (zh) 1993-08-06 1999-06-16 史密丝克莱恩比彻姆制药股份公司 氢化异喹啉衍生物
CA2683097A1 (en) 1998-03-10 1999-09-16 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
EP1333842B1 (en) * 2000-11-02 2006-08-30 Akzo Nobel N.V. Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
US7238778B2 (en) 2001-07-17 2007-07-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
CN1853722A (zh) * 2001-07-23 2006-11-01 科塞普特治疗公司 预防由抗精神病药物引起的体重增加的方法
US6679935B2 (en) * 2001-08-14 2004-01-20 Apex Advanced Technologies, Llc Lubricant system for use in powdered metals
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
EP1761497B1 (en) 2004-01-09 2008-09-03 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
PT1735308E (pt) * 2004-03-09 2008-12-02 Corcept Therapeutics Inc Moduladores dos receptores de glucocorticóides de azadecalina de anel fundido
DK1928840T3 (da) * 2005-04-05 2011-09-12 Hoffmann La Roche 1H-pyrazol-4-carboxamider, deres fremstilling og deres anvendelse som 11-beta-hydroxysteroid-dehydrogenaseinhibitorer
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US8309730B2 (en) 2007-11-01 2012-11-13 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor AP-1 and/or NF-kappab acitivity and use thereof
EP2247597A1 (en) * 2008-02-07 2010-11-10 Bristol-Myers Squibb Company Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
EP2429529B1 (en) 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
JP2013536250A (ja) 2010-08-27 2013-09-19 コーセプト セラピューティクス， インコーポレイテッド ピリジル−アミン縮合アザデカリンモジュレーター
WO2012094618A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US20130225633A1 (en) 2012-02-27 2013-08-29 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP4434584A3 (en) * 2012-05-25 2024-11-20 Corcept Therapeutics Incorporated Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3074011T3 (pl) 2013-11-25 2020-01-31 Corcept Therapeutics Incorporated Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12514849B2 (en) 2018-12-19 2026-01-06 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Also Published As

Publication number Publication date
PT3074011T (pt) 2019-09-17
PL3848027T3 (pl) 2023-07-24
EP4219494A1 (en) 2023-08-02
JP2016537394A (ja) 2016-12-01
US20190241563A1 (en) 2019-08-08
JP2024170470A (ja) 2024-12-10
AU2014352915B2 (en) 2018-03-15
US20150148341A1 (en) 2015-05-28
ZA201604026B (en) 2019-03-27
PT3848027T (pt) 2023-05-11
PL3560493T3 (pl) 2021-10-04
US20230167111A1 (en) 2023-06-01
CN106029066A (zh) 2016-10-12
CN109761976B (zh) 2021-11-23
IL245848A0 (en) 2016-07-31
JP2021073315A (ja) 2021-05-13
BR112016011826B1 (pt) 2022-09-27
KR102352737B1 (ko) 2022-01-17
AU2014352915A1 (en) 2016-06-30
US20210139478A1 (en) 2021-05-13
US20200361935A1 (en) 2020-11-19
EP3074011A1 (en) 2016-10-05
US20190048004A1 (en) 2019-02-14
US20190135805A1 (en) 2019-05-09
ES2869172T3 (es) 2021-10-25
EP3560493B1 (en) 2021-03-31
RU2674983C1 (ru) 2018-12-14
MX2016006725A (es) 2016-09-09
FI3848027T3 (fi) 2023-05-04
DK3074011T3 (da) 2019-09-30
US11370789B2 (en) 2022-06-28
EP3074011B1 (en) 2019-07-24
US11560379B2 (en) 2023-01-24
CA2931302C (en) 2021-12-07
ES2743620T3 (es) 2020-02-20
KR20160089506A (ko) 2016-07-27
EP3074011A4 (en) 2017-05-31
WO2015077530A1 (en) 2015-05-28
ES2943542T3 (es) 2023-06-14
IL245848B (en) 2020-08-31
CN106029066B (zh) 2019-03-15
JP2019094355A (ja) 2019-06-20
RU2016123449A (ru) 2017-12-28
CA2931302A1 (en) 2015-05-28
JP2018012734A (ja) 2018-01-25
US12139486B2 (en) 2024-11-12
US10047082B2 (en) 2018-08-14
MY180141A (en) 2020-11-23
JP2023011052A (ja) 2023-01-20
US20250034140A1 (en) 2025-01-30
MX368167B (es) 2019-09-23
EP3848027A1 (en) 2021-07-14
BR112016011826A2 (enExample) 2017-08-08
PH12016500968B1 (en) 2019-11-08
PH12016500968A1 (en) 2016-07-18
PL3074011T3 (pl) 2020-01-31
EP3560493A1 (en) 2019-10-30
US10787449B2 (en) 2020-09-29
CN109761976A (zh) 2019-05-17
EP3848027B1 (en) 2023-04-05
NZ720969A (en) 2021-05-28
DK3848027T3 (da) 2023-05-01
US10323034B2 (en) 2019-06-18

Similar Documents

Publication Publication Date Title
JP6516743B2 (ja) オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子
WO2015077537A1 (en) Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators
HK40056814B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40056814A (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40009157A (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40009157B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40002681B (zh) 八氢稠合的氮杂萘烷糖皮质激素受体调节剂
HK1228803A1 (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK1228803B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK40002681A (en) Octahydro fused azadecalin glucocorticoid receptor modulators
NZ720969B2 (en) Octahydro fused azadecalin glucocorticoid receptor modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190416

R150 Certificate of patent or registration of utility model

Ref document number: 6516743

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250